Cancer cells do things a little
differently. First, most cancer cells continue to depend
on glucose, but switch over from cellular respiration
(which requires oxygen), to glycolysis (which can happen
with or without oxygen). Researcher sticks with cellular
respiration, but switch from metabolizing sugar to
metabolizing protein, or more precisely amino acids,
which are the building blocks of protein. Healthy cells
don't need to metabolize protein. The current study
shows that cancer stem cells do need to metabolize
protein. And this difference is proving to be an
Achilles' heel that allows researchers to target cancer
stem cells without harming healthy cells the approach
has already proven effective in clinical trials against
acute myeloid leukemia (AML) and holds promise for other
cancers including breast, pancreatic, and liver.
Conventional chemotherapy is not effective for most
patients with acute myeloid leukemia. The new results
with venetoclax look very promising. The current study
circles back to pinpoint why the clinical trial was so
successful. Study showed that leukemia stem cells do not
(or are perhaps unable) to switch from cellular
respiration to glycolysis like more mature cancer cells.
Instead, switch from metabolizing glucose to
metabolizing amino acids in fact, researcher come to
absolutely depend on metabolizing amino acids for
energy, so much so that when the ability of leukemia
stem cells to uptake amino acids is interrupted, these
cells die. The drug venetoclax stops leukemia stem cells
from being able to use amino acids for energy. In the
lab and now in the clinic, when researchers treated AML
patients with venetoclax, leukemia stem cells died.
Importantly, because healthy cells do not depend on
amino acid metabolism, venetoclax killed leukemia stem
cells without harming healthy cells. The group's future
work hopes to explore the possibility of inhibiting
lipid metabolism along with amino acid metabolism for
use with AML patients whose cancers have resisted or
relapsed after previous therapies.
|